This report provides a comprehensive analysis of the global cancer vaccines market, which is poised for significant growth driven by rising cancer prevalence and breakthroughs in mRNA and immunotherapy technologies. The study examines market dynamics across preventive and therapeutic segments, highlighting the dominance of preventive vaccines and intramuscular administration routes. While North America maintains a leading market share due to advanced healthcare infrastructure, the report also explores key industry players, technological innovations, and strategic R&D investments shaping the future landscape.

Market Overview

The global cancer vaccines market is projected to grow from USD 10.61 billion in 2024 to surpass USD 20.47 billion in 2032, exhibiting a significant compound annual growth rate (CAGR) of 8.6%.

This market is witnessing robust growth, fueled by several key factors:

• Rising cancer prevalence.
• Advancements in immunotherapy technologies, such as mRNA platforms.
• Innovation driven by preventive vaccines (e.g., Gardasil for HPV) and therapeutic candidates (e.g., neoantigen vaccines).
• Strong R&D investments, particularly in North America and Europe.
• Increasing demand for personalized therapies.

Market Segmentation

By Type

• Preventive Vaccines: This segment accounted for the highest share in 2023 and is anticipated to lead the market. Growth is driven by increasing awareness of disease prevention, government immunization programs, and technological advancements in vaccine development. Emerging technologies like mRNA platforms are expected to enhance vaccine efficacy and accessibility, further boosting segmental growth.
• Therapeutic Vaccines: Including Neoantigen cancer vaccines and other cancer vaccines.

By Route of Administration

• Intramuscular (IM): This segment accounted for the largest share in the market. The IM route is expected to lead due to established practices, high efficacy in vaccine administration, and the ability to create an effective immune response. It guarantees high efficiency of vaccine absorption and compatibility with various formulations, making it highly appropriate for both preventive and treatment cancer vaccines. Additionally, its ease of use in clinical and outpatient settings, combined with minimal training requirements for healthcare providers, enhances accessibility and scalability for mass immunization programs.
• Intravenous
• Other Routes of Administration

By Indication

• Cervical cancer
• Prostate cancer
• Other indications

By End User

• Hospitals
• Others

By Region

• North America: This region dominated the cancer vaccines market in 2023 and is estimated to continue its dominance during the forecast period. Growth is accelerated by advanced healthcare infrastructure, high levels of investment in biotechnology, and a strong presence of leading pharmaceutical companies driving innovation.
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Competitive Landscape

Key Players

Major players operating in the cancer vaccines market include:

• Merck & Co., Inc. (US)
• GSK plc (UK)
• Dendreon Pharmaceuticals LLC (US)
• JW CreaGene (Korea)
• Serum Institute of India Pvt. Ltd. (India)
• Verity Pharmaceuticals, Inc. (Canada)
• Wantai BioPharm (China)
• Vaccinogen (US)
• Shanghai Zerun Biotechnology Co., Ltd. (China)

Research Methodology & Interview Insights

In-depth interviews were conducted with Chief Executive Officers (CEOs), Directors, and other executives from various key organizations. The primary interviews are categorized as follows:

• By Respondent:
• Supply Side: 65%
• Demand Side: 35%
• By Designation:
• Managers: 45%
• CXO & Directors: 30%
• Executives: 25%
• By Region:
• North America: 40%
• Europe: 25%
• Asia-Pacific: 25%
• Latin America: 5%
• Middle East & Africa: 5%

Market Dynamics

Drivers, Restraints, Opportunities, and Challenges

• Drivers:
• Increasing Awareness and Preventive Healthcare Measures
• Rising Cancer Incidence Globally
• Increased investments into R&D of Neoantigen cancer vaccines
• Technological Advancements in Immunotherapy
• Restraints:
• Lengthy Clinical Trial Processes
• Vaccine Hesitancy
• Limited Adoption
• High Development and Manufacturing Costs
• Opportunities:
• Collaborations & Strategic Partnerships
• Incorporation of Artificial Intelligence (AI) & Big Data
• Challenges:
• Personalized Medicine & Heterogeneity of Cancer Types
• Competition from Alternative Therapies

Research Coverage & Scope

This report provides a comprehensive analysis of the cancer vaccines market, covering:

• Detailed Segmentation: Type, technology (cell-based vaccines, recombinant, others), route of administration, indication, end user, and region.
• Market Analysis: In-depth exploration of drivers, restraints, challenges, and opportunities.
• Competitive Intelligence: Detailed insights into key industry players, including their business overview, products, solutions, key strategies, collaborations, partnerships, agreements, new launches, acquisitions, and recent developments.
• Product Development & Innovation: Insights into upcoming manufacturing technologies, R&D activities, and new product launches.
• Market Development & Diversification: Analysis of lucrative markets across varied regions, untapped geographies, and recent investments.

Key Benefits of the Report

• For Market Leaders and New Entrants: Provides close approximations of revenue numbers for the cancer vaccines market and its subsegments.
• For Stakeholders: Assists in understanding the competitive landscape, enabling better business positioning and the development of suitable go-to-market strategies.
• Market Intelligence: Enables stakeholders to understand the market's pulse by providing critical information on drivers, restraints, opportunities, and challenges.

• 1 INTRODUCTION 26

  • 1.1 STUDY OBJECTIVES 26

  • 1.2 MARKET DEFINITION 26

  • 1.3 MARKET SCOPE 27

    • 1.3.1 MARKETS COVERED & REGIONAL SEGMENTATION 27

    • 1.3.2 INCLUSIONS & EXCLUSIONS 28

    • 1.3.3 YEARS CONSIDERED 28

    • 1.3.4 CURRENCY CONSIDERED 28

  • 1.4 STAKEHOLDERS 29

• 2 RESEARCH METHODOLOGY 30

  • 2.1 RESEARCH DATA 30

    • 2.1.1 SECONDARY DATA 31

    • 2.1.2 PRIMARY DATA 32

  • 2.2 MARKET ESTIMATION METHODOLOGY 33

    • 2.2.1 MARKET ESTIMATION 33

    • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS 35

    • 2.2.3 TOP-DOWN APPROACH 36

  • 2.3 MARKET GROWTH RATE PROJECTION 37

  • 2.4 DATA TRIANGULATION 39

  • 2.5 RESEARCH ASSUMPTIONS 39

  • 2.6 RESEARCH LIMITATIONS 40

  • 2.7 RISK ANALYSIS 41

• 3 EXECUTIVE SUMMARY 42

• 4 PREMIUM INSIGHTS 47

  • 4.1 CANCER VACCINES MARKET OVERVIEW 47

  • 4.2 NORTH AMERICA: CANCER VACCINES MARKET, BY TECHNOLOGY AND COUNTRY (2023) 48

  • 4.3 CANCER VACCINES MARKET SHARE, BY TYPE, 2024 VS. 2032 48

  • 4.4 CANCER VACCINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 49

• 5 MARKET OVERVIEW 50

  • 5.1 INTRODUCTION 50

  • 5.2 MARKET DYNAMICS 50

    • 5.2.1 DRIVERS 51

      • 5.2.1.1 Increased investments in neoantigen cancer vaccine R&D 51
      • 5.2.1.2 Technological advancements in immunotherapy 51
      • 5.2.1.3 Increasing awareness and preventive healthcare measures 52
      • 5.2.1.4 Rising cancer incidence globally 53

    • 5.2.2 RESTRAINTS 53

      • 5.2.2.1 High development and manufacturing costs 53
      • 5.2.2.2 Lengthy clinical trial processes & vaccine hesitancy and limited adoption 54

    • 5.2.3 OPPORTUNITIES 55

      • 5.2.3.1 Collaborations and strategic partnerships 55
      • 5.2.3.2 Incorporation of AI and big data 56

    • 5.2.4 CHALLENGES 57

      • 5.2.4.1 Personalized medicine and heterogeneity of cancer types 57
      • 5.2.4.2 Competition from alternative therapies 57

  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS 58

  • 5.4 VALUE CHAIN ANALYSIS 59

  • 5.5 ECOSYSTEM ANALYSIS 60

    • 5.5.1 RAW MATERIAL PROVIDERS 61

    • 5.5.2 PRODUCT PROVIDERS 62

    • 5.5.3 END USERS 63

    • 5.5.4 REGULATORY LANDSCAPE 63

  • 5.6 TECHNOLOGY ANALYSIS 64

    • 5.6.1 KEY TECHNOLOGIES 65

      • 5.6.1.1 mRNA-based vaccines 65
      • 5.6.1.2 Dendritic cell vaccines 65
      • 5.6.1.3 Recombinant vector-based vaccines 66

    • 5.6.2 COMPLEMENTARY TECHNOLOGIES 66

      • 5.6.2.1 Artificial Intelligence (AI) and Machine Learning (ML) 66
      • 5.6.2.2 Adjuvants for immuno-stimulation 66

    • 5.6.3 ADJACENT TECHNOLOGIES 67

      • 5.6.3.1 CAR T-cell therapy 67
      • 5.6.3.2 CRISPR-based gene editing 67

  • 5.7 PATENT ANALYSIS 68

    • 5.7.1 METHODOLOGY 68

    • 5.7.2 NUMBER OF PATENTS FILED 68

    • 5.7.3 INNOVATIONS AND PATENT APPLICATIONS 68

  • 5.8 PRICING ANALYSIS 71

    • 5.8.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, 2021-2023 71

    • 5.8.2 AVERAGE SELLING PRICE, BY REGION, 2023 72

  • 5.9 KEY CONFERENCES & EVENTS, 2024-2O25 73

  • 5.10 REGULATORY LANDSCAPE 74

    • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74

    • 5.10.2 REGULATORY FRAMEWORK 77

      • 5.10.2.1 North America 77
      • 5.10.2.2 Europe 77
      • 5.10.2.3 Asia Pacific 77

  • 5.11 INVESTMENT & FUNDING SCENARIO 78

  • 5.12 PORTER’S FIVE FORCES ANALYSIS 80

    • 5.12.1 INTENSITY OF COMPETITIVE RIVALRY 81

    • 5.12.2 BARGAINING POWER OF SUPPLIERS 81

    • 5.12.3 BARGAINING POWER OF BUYERS 81

    • 5.12.4 THREAT OF SUBSTITUTES 81

    • 5.12.5 THREAT OF NEW ENTRANTS 81

  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA 82

    • 5.13.1 KEY STAKEHOLDERS 82

    • 5.13.2 KEY BUYING CRITERIA 83

  • 5.14 TRADE ANALYSIS 85

    • 5.14.1 IMPORT DATA FOR HS CODE 300241 85

    • 5.14.2 EXPORT DATA FOR HS CODE 300241 86

  • 5.15 IMPACT OF AI/GEN AI ON CANCER VACCINES MARKET 88

  • 5.16 PIPELINE ANALYSIS 90

• 6 CANCER VACCINES MARKET, BY TYPE 91

  • 6.1 INTRODUCTION 92

  • 6.2 PREVENTIVE VACCINES 92

    • 6.2.1 NATIONAL IMMUNIZATION PROGRAMS & BIOTECHNOLOGY INNOVATIONS TO DRIVE MARKET GROWTH 92

  • 6.3 THERAPEUTIC VACCINES 95

    • 6.3.1 NEOANTIGEN CANCER VACCINES 99

      • 6.3.1.1 Personalized nature of neoantigen cancer vaccines to propel market growth 99

    • 6.3.2 OTHER THERAPEUTIC VACCINES 102

• 7 CANCER VACCINES MARKET, BY TECHNOLOGY 106

  • 7.1 INTRODUCTION 107

  • 7.2 CELL-BASED VACCINES 107

    • 7.2.1 ADVANCEMENTS IN MANUFACTURING PROCESSES TO DRIVE MARKET GROWTH 107

  • 7.3 RECOMBINANT VACCINES 110

    • 7.3.1 GLOBAL VACCINATION INITIATIVES TO PROPEL MARKET 110

  • 7.4 OTHER VACCINE TECHNOLOGIES 113

• 8 CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION 117

  • 8.1 INTRODUCTION 118

  • 8.2 INTRAMUSCULAR ROUTE 118

    • 8.2.1 TECHNOLOGICAL ADVANCEMENTS IN VACCINE DELIVERY TO SUPPORT MARKET GROWTH 118

  • 8.3 OTHER ROUTES OF ADMINISTRATION 121

• 9 CANCER VACCINES MARKET, BY INDICATION 125

  • 9.1 INTRODUCTION 126

  • 9.2 CERVICAL & RELATED CANCERS 126

    • 9.2.1 RISING CERVICAL CANCER PREVALENCE TO SUPPORT MARKET GROWTH 126

  • 9.3 OTHER INDICATIONS 129

• 10 CANCER VACCINES MARKET, BY END USER 133

  • 10.1 INTRODUCTION 134

  • 10.2 HOSPITALS 134

    • 10.2.1 RISING CANCER PREVALENCE TO SUPPORT MARKET GROWTH 134

  • 10.3 SPECIALTY CLINICS & CENTERS 137

    • 10.3.1 INCREASING AWARENESS AND ACCESS TO PROPEL MARKET 137

• 11 CANCER VACCINES MARKET, BY REGION 141

  • 11.1 INTRODUCTION 142

  • 11.2 ASIA PACIFIC 142

    • 11.2.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 143

    • 11.2.2 CHINA 147

      • 11.2.2.1 Government support & strategic initiatives by key players to strengthen biotechnology sector in China 147

    • 11.2.3 JAPAN 150

      • 11.2.3.1 Government initiatives for vaccines to boost market 150

    • 11.2.4 INDIA 152

      • 11.2.4.1 Growth of biotechnology sector and development of new vaccines to drive market 152

    • 11.2.5 SOUTH KOREA 155

      • 11.2.5.1 Commitment to cancer immunotherapy to expand cancer vaccine sector 155

    • 11.2.6 REST OF ASIA PACIFIC 157

  • 11.3 NORTH AMERICA 160

    • 11.3.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 160

    • 11.3.2 US 164

      • 11.3.2.1 US to dominate North American market during forecast period 164

    • 11.3.3 CANADA 167

      • 11.3.3.1 Increasing government funding for vaccine research to drive market growth in Canada 167

  • 11.4 EUROPE 169

    • 11.4.1 MACROECONOMIC OUTLOOK FOR EUROPE 169

    • 11.4.2 GERMANY 173

      • 11.4.2.1 Increasing investments by key players and growing funding from government organizations to drive market 173

    • 11.4.3 UK 175

      • 11.4.3.1 Rising investments in vaccine development to boost market growth 175

    • 11.4.4 FRANCE 178

      • 11.4.4.1 Support for biotechnology and research to drive market growth 178

    • 11.4.5 ITALY 181

      • 11.4.5.1 Government initiatives for vaccine development to boost market growth 181

    • 11.4.6 SPAIN 183

      • 11.4.6.1 Increasing investments in vaccine development by government and private organizations to support market growth 183

    • 11.4.7 REST OF EUROPE 186

  • 11.5 LATIN AMERICA 188

    • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 188

    • 11.5.2 BRAZIL 191

      • 11.5.2.1 Proactive healthcare policies to support market growth 191

    • 11.5.3 MEXICO 194

      • 11.5.3.1 Government commitment to immunization programs to fuel growth 194

    • 11.5.4 REST OF LATIN AMERICA 196

  • 11.6 MIDDLE EAST 198

    • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 198

    • 11.6.2 GCC COUNTRIES 202

    • 11.6.3 REST OF MIDDLE EAST 204

  • 11.7 AFRICA 206

    • 11.7.1 INCREASING INVESTMENTS IN CANCER VACCINE IMMUNIZATION PROGRAMS TO SUPPORT MARKET GROWTH 206

    • 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 207

• 12 COMPETITIVE LANDSCAPE 210

  • 12.1 OVERVIEW 210

  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023 210

    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CANCER VACCINES MARKET 210

  • 12.3 REVENUE ANALYSIS, 2019-2023 212

  • 12.4 MARKET RANKING, 2023 AND 2032 212

  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 214

    • 12.5.1 STARS 214

    • 12.5.2 EMERGING LEADERS 214

    • 12.5.3 PERVASIVE PLAYERS 215

    • 12.5.4 PARTICIPANTS 215

    • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 216

      • 12.5.5.1 Company footprint 216
      • 12.5.5.2 Region footprint 216
      • 12.5.5.3 Type footprint 217
      • 12.5.5.4 Technology footprint 217
      • 12.5.5.5 Route of administration footprint 218

  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 218

    • 12.6.1 PROGRESSIVE COMPANIES 218

    • 12.6.2 RESPONSIVE COMPANIES 218

    • 12.6.3 DYNAMIC COMPANIES 218

    • 12.6.4 STARTING BLOCKS 219

    • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 220

  • 12.7 COMPANY VALUATION & FINANCIAL METRICS 221

    • 12.7.1 FINANCIAL METRICS 221

    • 12.7.2 COMPANY VALUATION 221

  • 12.8 BRAND/PRODUCT COMPARISON 222

  • 12.9 COMPETITIVE SCENARIO 222

    • 12.9.1 PRODUCT LAUNCHES & APPROVALS 222

    • 12.9.2 DEALS 223

    • 12.9.3 EXPANSIONS 224

• 13 COMPANY PROFILES 225

  • 13.1 KEY PLAYERS 225

    • 13.1.1 MERCK & CO., INC 225

      • 13.1.1.1 Business overview 225
      • 13.1.1.2 Products offered 226
      • 13.1.1.3 Recent developments 227
        • 13.1.1.3.1 Deals 227
        • 13.1.1.3.2 Expansions 227
      • 13.1.1.4 MnM view 228
        • 13.1.1.4.1 Key strengths 228
        • 13.1.1.4.2 Strategic choices 228
        • 13.1.1.4.3 Weaknesses & competitive threats 228

    • 13.1.2 GSK PLC 229

      • 13.1.2.1 Business overview 229
      • 13.1.2.2 Products offered 230
      • 13.1.2.3 Recent developments 231
        • 13.1.2.3.1 Product approvals 231
      • 13.1.2.4 MnM view 231
        • 13.1.2.4.1 Key strengths 231
        • 13.1.2.4.2 Strategic choices 231
        • 13.1.2.4.3 Weaknesses & competitive threats 231

    • 13.1.3 DENDREON PHARMACEUTICALS LLC. (SANPOWER GROUP) 232

      • 13.1.3.1 Business overview 232
      • 13.1.3.2 Products offered 232
      • 13.1.3.3 MnM view 233
        • 13.1.3.3.1 Key strengths 233
        • 13.1.3.3.2 Strategic choices 233
        • 13.1.3.3.3 Weaknesses & competitive threats 233

    • 13.1.4 JW CREAGENE (JW SHINYAK) 234

      • 13.1.4.1 Business overview 234
      • 13.1.4.2 Products offered 234

    • 13.1.5 SERUM INSTITUTE OF INDIA PVT. LTD 235

      • 13.1.5.1 Business overview 235
      • 13.1.5.2 Products offered 235
      • 13.1.5.3 Recent developments 236
        • 13.1.5.3.1 Product launches 236
        • 13.1.5.3.2 Deals 236

    • 13.1.6 VERITY PHARMACEUTICALS, INC 237

      • 13.1.6.1 Business overview 237
      • 13.1.6.2 Products offered 237
      • 13.1.6.3 Recent developments 238
        • 13.1.6.3.1 Product approvals 238

    • 13.1.7 WANTAI BIOPHARM 239

      • 13.1.7.1 Business overview 239
      • 13.1.7.2 Products offered 239

    • 13.1.8 SHANGHAI ZERUN BIOTECH CO., LTD. (WALVAX BIOTECHNOLOGY CO., LTD.) 240

      • 13.1.8.1 Business overview 240
      • 13.1.8.2 Products offered 240
      • 13.1.8.3 Recent developments 241
        • 13.1.8.3.1 Product approvals 241

    • 13.1.9 VACCINOGEN 242

      • 13.1.9.1 Business overview 242
      • 13.1.9.2 Products offered 242

  • 13.2 OTHER PLAYERS (COMPANIES WITH PRODUCTS UNDER CLINICAL STUDIES) 243

    • 13.2.1 BIONTECH 243

      • 13.2.1.1 BioNTech: Products under clinical studies 243

    • 13.2.2 GRITSTONE BIO 244

      • 13.2.2.1 Gritstone Bio: Products under clinical studies 244

    • 13.2.3 OSE-IMMUNO 245

      • 13.2.3.1 OSE-Immuno: Products under clinical studies 245

    • 13.2.4 OBI PHARMA 246

      • 13.2.4.1 OBI Pharma: Products under clinical studies 246

    • 13.2.5 SHANGHAI BOVAX BIOTECHNOLOGY CO., LTD 247

      • 13.2.5.1 Shanghai Bovax Biotechnology: Products under clinical studies 247

    • 13.2.6 MODERNA INC 248

      • 13.2.6.1 Moderna: Products under clinical studies 248

    • 13.2.7 BEIJING SINOCELL BIOTECHNOLOGY GROUP CO., LTD 249

      • 13.2.7.1 Beijing Sinocell Biotechnology Group: Products under clinical studies 249

    • 13.2.8 GREENWICH LIFESCIENCES, INC 250

      • 13.2.8.1 Greenwich LifeSciences: Products under clinical studies 250

    • 13.2.9 ASTON SCI. INC 251

      • 13.2.9.1 Aston Sci.: Products under clinical studies 251

    • 13.2.10 TRANSGENE 252

      • 13.2.10.1 Transgene: Products under clinical studies 252

    • 13.2.11 SELLAS LIFE SCIENCES GROUP INC 253

      • 13.2.11.1 Sellas Life Sciences Group: Products under clinical studies 253

• 14 APPENDIX 254

  • 14.1 DISCUSSION GUIDE 254

  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 259

  • 14.3 CUSTOMIZATION OPTIONS 261

  • 14.4 RELATED REPORTS 261

  • 14.5 AUTHOR DETAILS 262